A Phase 3 interventional study of Rituximab in Lymphoma, Follicular, sponsored by Hoffmann-La Roche. Completed at 21 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.
Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 42nd largest by enrollment of the 188 interventional ones that give a count, is one of 13 that started in 2005, is one of 35 in phase 3, and was the 164th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 129 · Phase 3 37
First in 1997; this study’s year is marked. 13 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 188 interventional studies. Of the 150 that completed or were terminated, 75 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 194 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 3, and was the 12th registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
5 of the studies testing rituximab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT01473628M.D. Anderson Cancer CenterRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | 2027-05-20 |
| NCT04998669Juan P. Alderuccio, MDLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 194 studies testing rituximab in Lymphoma, Follicular, from their registry updates:
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
Drug: Rituximab
Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
Also known as: MabThera/Rituxan
Event-free Survival
Event-free survival (EFS) was defined as the time from baseline (Week 0) to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first. Mean EFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population (patients who received at least one maintenance MabThera infusion) was used for this analysis.
Time frame: From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years
Number of Participants With Adverse Events (AEs)
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage, or results in death
Time frame: Up to 27 months
Overall Survival (OS)
Overall survival, defined as the time between baseline (Week 0) and the date of death irrespective of the cause of death. Mean OS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.
Time frame: From randomization until death, assessed up to 5 years
Time to Progression (TTP)
Time to progression (TTP) defined as time from baseline to disease progression or relapse, death from the follicular lymphoma or institution of a new regimen because of the follicular lymphoma. Mean TTP was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.
Time frame: From baseline (Week 0) to disease progression, relapse, death from the follicular lymphoma or institution of a new regimen, whichever occurs first, assessed up to 5 years
Time to Next Anti-lymphoma Treatment (TTNLT)
Time to next anti-lymphoma treatment (TTNLT) defined as time from baseline to institution of a new antilymphoma regimen (including chemo-, radio- or immunotherapies). Mean TTNLT was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
Time frame: From baseline (Week 0) to institution of a new antilymphoma regimen, assessed up to 5 years
Duration of Response (DR)
Duration of Response (DR) defined as time from first documented response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DR was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
Time frame: From first documented response to induction treatment to relapse or progression or death, assessed up to 5 years
Disease-free Survival (DFS)
Disease free survival (DFS) being defined as time from first documented complete response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
Time frame: From first documented complete response to induction treatment to relapse or progression or death, whichever occurs first, assessed up to 5 years
This study was conducted between 08 July 2005 to 12 Aug 2013 at 15 sites in Hungary.
| Milestone | Rituximab |
|---|---|
| Started | 124 |
| Completed | 69 |
| Not completed | 55 |
| Withdrew: Adverse event | 6 |
| Withdrew: Physician decision | 3 |
| Withdrew: Progression of the disease | 18 |
| Withdrew: New anti-lymphoma treatment | 1 |
| Withdrew: Non-compliance | 9 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Complete remission | 7 |
| Withdrew: Unknown reason | 1 |
Event-free survival (EFS) was defined as the time from baseline (Week 0) to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first. Mean EFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population (patients who received at least one maintenance MabThera infusion) was used for this analysis.
| months | Rituximab |
|---|---|
| Event-free Survival | 53.944 (50.242 to 57.647) |
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage, or results in death
| participants | Rituximab |
|---|---|
| SAEs | 14 |
| Non serious AEs | 32 |
Overall survival, defined as the time between baseline (Week 0) and the date of death irrespective of the cause of death. Mean OS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.
| months | Rituximab |
|---|---|
| Overall Survival (OS) | 72.959 (70.303 to 75.616) |
Time to progression (TTP) defined as time from baseline to disease progression or relapse, death from the follicular lymphoma or institution of a new regimen because of the follicular lymphoma. Mean TTP was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.
| months | Rituximab |
|---|---|
| Time to Progression (TTP) | 56.024 (52.532 to 59.516) |
Time to next anti-lymphoma treatment (TTNLT) defined as time from baseline to institution of a new antilymphoma regimen (including chemo-, radio- or immunotherapies). Mean TTNLT was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
| months | Rituximab |
|---|---|
| Time to Next Anti-lymphoma Treatment (TTNLT) | 59.236 (56.318 to 62.153) |
Duration of Response (DR) defined as time from first documented response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DR was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
| months | Rituximab |
|---|---|
| Duration of Response (DR) | 63.159 (59.29 to 67.029) |
Disease free survival (DFS) being defined as time from first documented complete response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.
| months | Rituximab |
|---|---|
| Disease-free Survival (DFS) | 66.737 (63.808 to 69.666) |
Collected over Up to 27 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 14/124 (11.3%) | 3/124 (2.4%) |
| Event | Rituximab |
|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 2/124 |
| AgranulocytosisBlood and lymphatic system disorders | 1/124 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/124 |
| NeutropeniaBlood and lymphatic system disorders | 1/124 |
| Abdominal discomfortGastrointestinal disorders | 1/124 |
| DiarrhoeaGastrointestinal disorders | 1/124 |
| Gastric ulcerGastrointestinal disorders | 1/124 |
| Oral disorderGastrointestinal disorders | 1/124 |
| OedemaGeneral disorders | 1/124 |
| Acute hepatitis BInfections and infestations | 1/124 |
| Event | Rituximab |
|---|---|
| Diabetes mellitusEndocrine disorders | 3/124 |
| Age, Categorical(Participants) | Rituximab |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 102 |
| >=65 years | 22 |
| Age, Continuous(years) | Rituximab |
|---|---|
| Median | 53 (26 to 81) |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 84 |
| Male | 40 |
The record gives a start of Jul 2005, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab